Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

The NHS England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML).

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Today’s positive decision follows the manufacturer, Daiichi Sankyo, offering a fair price for the treatment that the National Institute for Health and Care Excellence (NICE) determined to be ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

This journal utilises an Online Peer Review Service (OPRS) for submissions. By clicking "Continue" you will be taken to our partner site https://mc.manuscriptcentral ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...

DelveInsight's CEACAM5 Drugs Market Insights report includes a comprehensive understanding of current treatment practices, ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

As a result, commercial teams are evolving as valuable partners to HCPs. From educating key experts before launch and ...